首页> 美国卫生研究院文献>Journal of Lipid Research >Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis
【2h】

Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis

机译:非诺贝特和PBA可防止脂肪酸诱导的人肝癌细胞和丙型肝炎病毒引起的脂肪变性中脂联素受体和pAMPK的丢失

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Adiponectin receptors play a key role in steatosis and inflammation; however, very little is known about regulation of adiponectin receptors in liver. Here, we examined the effects of palmitate loading, endoplasmic reticulum (ER) stress, and the hypolipidemic agent fenofibrate on adiponectin receptor R2 (AdipoR2) levels and AMP-activated protein kinase (AMPK) in human hepatoma Huh7 cells and in Huh.8 cells, a model of hepatitis C-induced steatosis. Palmitate treatment reduced AdipoR2 protein and basal AMPK phosphorylation in Huh7 cells. Fenofibrate treatment preserved AdipoR2 and phosphorylated AMPK (pAMPK) levels in palmitate-treated cells accompanied by reduced triglyceride (TG) accumulation and less activation of ER stress markers CCAAT/enhancer binding (C/EBPβ) and eukaryotic translation initiation factor 2 α. ER stress agents thapsigargin and tunicamycin suppressed AdipoR2 and pAMPK levels in Huh7 cells, while fenofibrate and the chemical chaperone 4-phenylbutyrate (PBA) prevented these changes. AdipoR2 levels were lower in Huh.8 cells and fenofibrate treatment increased AdipoR2 while reducing activation of c-Jun N-terminal kinase and C/EBPβ expression without changing TG levels. Taken together, these results suggest that fatty acids and ER stress reduce AdipoR2 protein and pAMPK levels, while fenofibrate and PBA might be important therapeutic agents to correct lipid- and ER stress-mediated loss of AdipoR2 and pAMPK associated with nonalcoholic steatohepatitis.
机译:脂联素受体在脂肪变性和炎症中起关键作用。然而,对肝脏中脂联素受体的调控知之甚少。在这里,我们检查了人类肝癌Huh7细胞和Huh.8细胞中棕榈酸酯负载,内质网(ER)应激和降血脂药非诺贝特对脂联素受体R2(AdipoR2)水平和AMP激活的蛋白激酶(AMPK)的影响。 ,是丙型肝炎诱发脂肪变性的模型。棕榈酸酯处理可减少Huh7细胞中的AdipoR2蛋白和基础AMPK磷酸化。非诺贝特治疗可保持棕榈酸酯处理的细胞中AdipoR2和磷酸化AMPK(pAMPK)的水平,同时减少甘油三酸酯(TG)的积累,并减少ER应激标志物CCAAT /增强子结合(C /EBPβ)和真核翻译起始因子2α的活化。内质网应激药物毒胡萝卜素和衣霉素抑制了Huh7细胞中的AdipoR2和pAMPK水平,而非诺贝特和化学伴侣4-苯基丁酸酯(PBA)阻止了这些变化。 Huh.8细胞中的AdipoR2水平较低,非诺贝特治疗可增加AdipoR2,同时降低c-Jun N端激酶的激活和C /EBPβ的表达,而不会改变TG水平。总之,这些结果表明,脂肪酸和内质网应激可降低AdipoR2蛋白和pAMPK水平,而非诺贝特和PBA可能是纠正由脂质和内质网应激介导的与非酒精性脂肪性肝炎相关的AdipoR2和pAMPK丧失的重要治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号